Mitigation of CXCL10 secretion by metabolic disorder drugs in microglial-mediated neuroinflammation.
J Neuroimmunol
; 391: 578364, 2024 Jun 15.
Article
em En
| MEDLINE
| ID: mdl-38718558
ABSTRACT
Metabolic disorders are associated with several neurodegenerative diseases. We previously identified C-X-C motif chemokine ligand 10 (CXCL10), also known as interferon gamma-induced protein 10 (IP-10), as a major contributor to the type I interferon response in microglial-mediated neuroinflammation. Therefore, we hypothesized FDA-approved metabolic disorder drugs that attenuate CXCL10 secretion may be repurposed as a treatment for neurodegenerative diseases. Screening, dose curves, and cytotoxicity assays in LPS-stimulated microglia yielded treprostinil (hypertension), pitavastatin (hyperlipidemia), and eplerenone (hypertension) as candidates that significantly reduced CXCL10 secretion (in addition to other pro-inflammatory mediators) without impacting cell viability. Altogether, these data suggest metabolic disorder drugs that attenuate CXCL10 as potential treatments for neurodegenerative disease through mitigating microglial-mediated neuroinflammation.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Microglia
/
Quimiocina CXCL10
/
Doenças Neuroinflamatórias
Limite:
Animals
Idioma:
En
Revista:
J Neuroimmunol
Ano de publicação:
2024
Tipo de documento:
Article
País de afiliação:
Estados Unidos